OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) Director David Pelizzon sold 302,369 shares of the company’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total value of $6,352,772.69. Following the sale, the director directly owned 6,201,764 shares in the company, valued at $130,299,061.64. This represents a 4.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
OrthoPediatrics Stock Down 0.6%
Shares of NASDAQ KIDS opened at $21.56 on Friday. The stock has a market cap of $562.93 million, a P/E ratio of -12.83 and a beta of 0.99. The business’s fifty day simple moving average is $21.97 and its 200-day simple moving average is $19.02. OrthoPediatrics Corp. has a 12-month low of $14.42 and a 12-month high of $26.74. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. The firm had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. As a group, equities analysts predict that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.
Institutional Investors Weigh In On OrthoPediatrics
Analyst Upgrades and Downgrades
KIDS has been the topic of several analyst reports. Weiss Ratings raised shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Piper Sandler reiterated an “overweight” rating and set a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Needham & Company LLC increased their price objective on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. BTIG Research raised their price objective on shares of OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Finally, Truist Financial set a $22.00 price objective on shares of OrthoPediatrics in a report on Wednesday, August 5th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, OrthoPediatrics currently has a consensus rating of “Moderate Buy” and an average price target of $26.44.
View Our Latest Research Report on KIDS
About OrthoPediatrics
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
Featured Stories
- Five stocks we like better than OrthoPediatrics
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
